Cargando…

Functional characterization of two rare BCR–FGFR1(+) leukemias

8p11 myeloproliferative syndrome (EMS) represents a unique World Health Organization (WHO)-classified hematologic malignancy defined by translocations of the FGFR1 receptor. The syndrome is a myeloproliferative neoplasm characterized by eosinophilia and lymphadenopathy, with risk of progression to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnes, Evan J., Leonard, Jessica, Medeiros, Bruno C., Druker, Brian J., Tognon, Cristina E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2020
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133745/ https://www.ncbi.nlm.nih.gov/pubmed/31980503 http://dx.doi.org/10.1101/mcs.a004838

Ejemplares similares

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia
por: Watanabe-Smith, Kevin, et al.
Publicado: (2016)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Smith, Brittany M., et al.
Publicado: (2021)

Comprehensive molecular characterization of a rare case of Philadelphia chromosome–positive acute myeloid leukemia
por: Rosenberg, Mara W., et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia
por: Haslam, Karl, et al.
Publicado: (2012)

A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice
por: Johnson, Kara J., et al.
Publicado: (2009)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia
por: Khanna, Vishesh, et al.
Publicado: (2015)

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
por: Zabriskie, M S, et al.
Publicado: (2016)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells
por: Javidi-Sharifi, Nathalie, et al.
Publicado: (2019)

Revisiting NTRKs as an emerging oncogene in hematological malignancies
por: Joshi, Sunil K., et al.
Publicado: (2019)

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells
por: Javidi-Sharifi, Nathalie, et al.
Publicado: (2019)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations
por: Watanabe-Smith, Kevin, et al.
Publicado: (2017)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate
por: Chou, C. James, et al.
Publicado: (2008)

A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation
por: Villafuerte-Gutiérrez, Paola, et al.
Publicado: (2018)

Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR(+) Acute Lymphoblastic Leukemia
por: Mostufi-Zadeh-Haghighi, Gila, et al.
Publicado: (2023)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation
por: Peiris, Malalage N., et al.
Publicado: (2020)

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3 mutation-positive leukemia
por: Agarwal, Anupriya, et al.
Publicado: (2014)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts
por: Dima, Delia, et al.
Publicado: (2017)

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
por: Lamble, Adam J., et al.
Publicado: (2020)

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
por: Smith, Lindsay D., et al.
Publicado: (2019)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase
por: Hu, Tianxiang, et al.
Publicado: (2018)

Amplification of the BCR::ABL1 Fusion Gene: A Rare Phenomenon in B-cell Acute Lymphoblastic Leukemia
por: Ray, Debadrita, et al.
Publicado: (2023)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia
por: Ferrer, Gerardo
Publicado: (2018)

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
por: Gong, Z, et al.
Publicado: (2017)

Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report
por: Isaza, Alejandro Pineda, et al.
Publicado: (2023)

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review
por: Piedimonte, Monica, et al.
Publicado: (2019)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dlkcne97m0c6brtdde9ogvfda0